£420.00
Stockholm3 combines protein markers, genetic markers and clinical data in an algorithm for the purpose of detecting aggressive prostate cancer at an early stage
Stockholm3 combines protein markers, genetic markers and clinical data in an algorithm for the purpose of detecting aggressive prostate cancer at an early stage.
✔ Stockholm3 finds twice as many men with aggressive cancers compared to current clinical practice with PSA
✔ Stockholm3 decreases the number of unnecessary biopsies by 50% compared to current clinical practice with PSA
✔ Stockholm3 finds aggressive cancer also in men with low PSA values
✔ Stockholm3 is based on scientific clinical studies including more than 75,000 men
Stockholm3 combines protein markers, genetic markers and clinical data in an algorithm for the purpose of detecting aggressive prostate cancer at an early stage
